Compugen (NASDAQ:CGEN) – Equities researchers at Jefferies Group increased their Q2 2018 earnings estimates for shares of Compugen in a research note issued on Wednesday, May 9th. Jefferies Group analyst P. Welford now anticipates that the biotechnology company will earn ($0.20) per share for the quarter, up from their prior forecast of ($0.21). Jefferies Group also issued estimates for....More>>>
Pfizer Inc. (NYSE: PFE) shares were up marginally on Wednesday after the pharmaceutical giant announced that it would be committing over half a billion dollars to its venture capital arm.
Essentially the firm intends to invest $600 million in biotechnology and other emerging growth companies through Pfizer Ventures, the companys venture investment vehicle.
Additionally, Pfizer will....More>>>
On Wednesday, our Elite Opportunity Pronewsletter suggested going long again on small cap gene therapy stock Uniqure NV (NASDAQ: QURE):
QURE is showing signs of a tradable reversal as soon as early next year. Assuming one or both of these ideas start to find traction like they did the last time we suggested them, we could be looking at some pretty nice gains yet again. And, when you consider....More>>>
The current CAR-T party of two might have a couple of new companions on the way. And those new entrantscould bring some excitement to the party.
Only two chimeric antigen T-cell receptor (CAR-T) therapies are currently approved by the FDA — Novartis’Kymriah and Gilead Sciences’ Yescarta. Celgene (NASDAQ:CELG) and partner bluebird bio (NASDAQ:BLUE) announced good news for....More>>>
When biotech investors talk about the future of DNA sequencing, they inevitably focus on industry leader Illumina (NASDAQ:ILMN). But when biotech researchers talk about the future of DNA sequencing, the conversation almost always centers on privately held Oxford Nanopore Technologies, which is developing a new approach to reading genetic code called nanopore sequencing. The excitement isn’t....More>>>
Welcome to Biotech Analysis Central Daily News, a daily news report and analysis about what has happened lately in the biotech industry.
Regeneron and Alnylam Team Up For NASH Fibrosis Drug
News: Recently, Regeneron (REGN) and Alnylam (ALNY) stated that they will team up and co-develop a drug to treat non-alcoholic steatohepatitis (NASH) fibrosis. The goal of the partnership is to....More>>>
Atara Biotherapeutics (NASDAQ:ATRA) had its price target decreased by Citigroup from $25.00 to $23.00 in a report released on Monday. Citigroup currently has a sell rating on the biotechnology company’s stock.
ATRA has been the subject of a number of other reports. JPMorgan Chase & Co. assumed coverage on Atara Biotherapeutics in a report on Tuesday, April 10th. They issued an overweight....More>>>
News articles about Foster Wheeler (NASDAQ:FWLT) have been trending somewhat positive recently, according to Accern. The research firm scores the sentiment of news coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Foster Wheeler....More>>>
Roche ADRs (OTCQX:RHHBY) remain in a downtrend even as the company has increased its guidance, following detailed but interim Q1 results (no EPS reported), to modest organic growth this year, but high-single-digit growth including the effects of last December’s US tax legislation. Coming into the important ASCO (oncology) meeting this weekend, this article provides an....More>>>
Stocks ended mixedthough let’s face it, little changedas investors continue to wrestle with a world that’s more dangerous than ever and stocks that insist on just the opposite.
The S&P 500 dipped 0.1% to 2,163.78 today, while the Dow Jones Industrial Average rose 25.96 points, or 0.1%, to 18559.01, a new record high. The Nasdaq Composite declined 0.4%....More>>>